Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

7.340 +0.220 (+3.09%)
Streaming Delayed Price Updated: 10:54 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121,940
Open 7.400
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 7.120
Today's Range 7.310 - 7.400
52wk Range 6.820 - 14.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace

Performance

YTD
-21.75%
-21.75%
1 Month
+5.16%
+5.16%
3 Month
-0.20%
-0.20%
6 Month
-18.44%
-18.44%
1 Year
-47.08%
-47.08%

More News

Read More
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Via Benzinga
Exposures Glyphosate
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Via Benzinga
Topics Data Breach
Exposures Information Security
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
Via Benzinga
Exposures Glyphosate
Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades'
Via Benzinga
Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
Via Benzinga
Topics Bonds
Exposures Debt Markets
Bayer-Backed Boundless Bio Falls After IPO
Via Talk Markets
Dyadic Intl. Inc. (NASDAQ: DYAI) Potential Strategic Alliances with Future of Foods Boosts Stock as Key Conference Looms
Via AB Newswire
Topics Supply Chain
Exposures Supply Chain
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
Via Benzinga
Exposures Product Safety
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Glyphosate Legal
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
Via Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Via InvestorPlace
What's Going On With BridgeBio Pharma Stock On Monday?
Via Benzinga
Exposures Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
Via Investor's Business Daily
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
Via InvestorPlace
3 Overextended Stocks That Need to Slash Their Dividends ASAP
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.